Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPM.L Regulatory News (MPM)

  • There is currently no data for MPM

Rule 8.3- Minster Pharma PLC

13 Jan 2010 14:27

RNS Number : 4922F
VFT Ltd
13 January 2010
 



FORM 8.3

DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE

(Rule 8.3 of the City Code on Takeovers and Mergers)

 

1. KEY INFORMATION

Name of person dealing (Note 1)

VFT LTD

Company dealt in

MINSTER PHARMA PLC

Class of relevant security to which the dealings being disclosed relate (Note 2)

ORDINARY SHARES

Date of dealing

3/3/2005 12/1/2006 14/12/2005 7/1/2010

3/1/2006 13/1/2010

 

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

 

(a)

Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

 

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities 

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

 

(b)

Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

 Class of relevant security:

Long

Short

 

Number

(%)

Number

(%)

(1) Relevant securities 

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

 

(c) Rights to subscribe (Note 3)

 

Class of relevant security:

Details

3. DEALINGS (Note 4)

 

(a) Purchases and sales

 

Purchase/sale 

Number of securities

Price per unit (Note 5)

3/3/2005

14/12/2005

3/1/2006

12/1/2006

 7/1/2010 13/1/2010

2,000

2,500

2,500

3,000

150,000

450,000

£14.21

£1.034

£1.23

£1.25

£0.058

£0.058

Total 610,000

 

 

(b) Derivatives transactions (other than options)

 

Product name,

e.g. CFD

Long/short (Note 6)

Number of securities (Note 7)

Price per unit (Note 5)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

 

Product

name, e.g.

call option 

Writing,

selling,

purchasing,

varying etc.

Number of

securities to

which the

option

relates

(Note 7)

Exercise

price 

Type, e.g.

American,

European

etc.

Expiry

date

Option

money

paid/received

per unit (Note

5) 

 

 

(ii) Exercising

 

Product name, e.g. call option

Number of securities 

Exercise price per unit (Note 5)

 

(d) Other dealings (including new securities) (Note 4)

 

Nature of transaction (Note 8) 

Details

Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)

NO

 

Date of disclosure

13/1/10

Contact name

B LEMER

Telephone number

0207 739 6568

If a connected EFM, name of offeree/offeror with which connected

If a connected EFM, state nature of connection (Note 10)

Notes

The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETXXLFFBFFZBBK
Date   Source Headline
27th Jun 20087:00 amRNSAHS Meeting
25th Jun 200810:28 amRNSDirector/PDMR Shareholding
24th Jun 200810:23 amRNSResult of Annual General Meet
24th Jun 20087:00 amRNSAGM Statement
16th Jun 20087:30 amRNSTEMPUS study fully enrolled
4th Jun 20087:00 amRNSAnnual Report and Accounts
2nd Jun 20087:00 amRNSUS Marketing Consultant
22nd May 20087:00 amRNSPreliminary Results
12th Mar 20087:00 amRNSAura trial fully enrolled
5th Feb 20087:00 amRNSTEMPUS Trial Update
3rd Dec 20077:00 amRNSInterim Results
16th Oct 20077:00 amRNSTEMPUS trial starts in US
4th Oct 200711:06 amRNSChange of Registered Office
28th Sep 200711:32 amRNSDirector/PDMR Shareholding
17th Aug 20077:00 amRNSAIM Rule 26
16th Jul 200711:29 amRNSResult of AGM
16th Jul 20077:00 amRNSAGM Statement
2nd Jul 20074:13 pmRNSHolding(s) in Company
27th Jun 20077:01 amRNSIHS Scientific Meeting
21st Jun 20075:05 pmRNSAnnual Report and Accounts
13th Jun 20077:02 amRNSPreliminary Results
7th Jun 20077:02 amRNSAHS Scientific Meeting
1st Jun 20078:30 amRNSTotal Voting Rights
18th May 20079:20 amRNSAdditional Listing
30th Apr 20076:22 pmRNSHolding(s) in Company
30th Apr 200712:16 pmRNSTotal Voting Rights
11th Apr 20074:39 pmRNSConversion of Loan Note
2nd Apr 20073:27 pmRNSHolding(s) in Company
2nd Apr 20072:55 pmRNSHolding(s) in Company
2nd Apr 20071:26 pmRNSDirector/PDMR Shareholding
30th Mar 20079:32 amRNSTotal Voting Rights
27th Mar 20077:01 amRNSBoard Appointments
26th Mar 200710:31 amRNSResult of EGM
2nd Mar 20077:30 amRNSGPB17m fundraising
9th Jan 20077:01 amRNSPositive Tonabersat Study
20th Dec 20065:43 pmRNSTotal Voting Rights
1st Dec 20067:01 amRNSInterim Results
17th Nov 20067:01 amRNSPlacing
25th Oct 200610:20 amRNSResult of AGM
25th Oct 20067:01 amRNSAGM Statement
27th Sep 20067:00 amRNSNIH Collaboration
20th Sep 20067:02 amRNSPreliminary Results
7th Sep 20067:00 amRNSAdditional Indications
15th Aug 200611:37 amRNSNotification of Interests
20th Jun 20067:00 amRNSStart of Phase II Trial
24th May 20067:01 amRNSUCLA Collaboration
21st Mar 20067:00 amRNSStart of Phase II Trial
8th Mar 20067:03 amRNSChange of Adviser
13th Jan 20067:00 amPRNRe Agreement
8th Dec 20057:00 amPRNInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.